WHO halts Trump marketed COVID-19 drug after it fails to reduce death rate

The World Health Organization (WHO) has halted trials of malaria drug hydroxychloroquine and combination HIV drug lopinavir/ritonavir in coronavirus hospitalised patients after they failed to reduce mortality rate.

WHO made the announcement in the backdrop after 200,000 coronavirus cases were reported globally in a 24 hour period.

In a statement WHO said, “these interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalised COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect.”

Meanwhile, a WHO led team is working to see the effects of Gilead’s antiviral drug remdesivir on COVID-19. The European Commission on Friday gave remdesivir conditional approval for use after being shown to shorten hospital recovery times.

Around the world 5,500 coronavirus positive patients had been recruited for the clinical trial. The results are expected in two weeks.

Close to 18 vaccines around the world are in clinical trial stage while over 150 are under the development phase.

WHO’s epidemiologist specialist, Mike Ryan said vaccine candidates might show effectiveness by early 2021 and how soon mass production could start.